Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636435 | 1.00 | NAMPT (0.46) | NAMPTCYP17A1MAPKAPK2PSMB8MAPK14 | |
| SCHEMBL15079228 | 0.86 | SMN1; SMN2 (0.45) | P4HTM | |
| SCHEMBL30564676 | 0.86 | SMN1; SMN2 (0.45) | P4HTM | |
| SCHEMBL5153340 | 0.83 | NAMPT (0.50) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL2012546 | 0.83 | NAMPT (0.50) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL29929054 | 0.83 | P4HTM (0.54) | NAMPTCYP17A1P4HTM | |
| SCHEMBL1734048 | 0.83 | P4HTM (0.54) | NAMPTCYP17A1P4HTM | |
| SCHEMBL19470129 | 0.82 | NAMPT (0.49) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL64988 | 0.82 | MAPK1 (0.51) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 | |
| SCHEMBL925018 | 0.81 | NAMPT (0.48) | NAMPTCYP17A1MAPKAPK2PSMB8MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9120822-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-01 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG | 2015-03-12 | — | — | US | disclosed |
| US-8927541-B2 | Tricyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| EP-2513115-B1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| EP-2513115-A1 | TRICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011073378-A1 | TRICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245345-A1 | TRICYCLIC ANTIBIOTICS | CBR1, CBR3, C1S | NAMPT 2821/4885CYP17A1 1451/4885MAPKAPK2 4732/4885 |
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | NAMPT 998/4885CYP17A1 169/4885MAPKAPK2 3861/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | NAMPT 998/4885CYP17A1 169/4885MAPKAPK2 3861/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | NAMPT 395/4885CYP17A1 365/4885MAPKAPK2 2594/4885 |
| US-20150072975-A1 | TRICYCLIC ANTIBIOTICS | TREH, MRPL21, SPOUT1 | NAMPT 1088/4885CYP17A1 529/4885MAPKAPK2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.